摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

mer-[RuCl3(tetramethylene sulfoxide-S)2(tetramethylene sulfoxide-O)] | 134659-64-6

中文名称
——
中文别名
——
英文名称
mer-[RuCl3(tetramethylene sulfoxide-S)2(tetramethylene sulfoxide-O)]
英文别名
{mer-RuCl3(tetramethylenesulfoxide)3}
mer-[RuCl<sub>3</sub>(tetramethylene sulfoxide-S)2(tetramethylene sulfoxide-O)]化学式
CAS
134659-64-6
化学式
C12H24Cl3O3RuS3
mdl
——
分子量
519.948
InChiKey
YXSQHIVGUDKPCH-UHFFFAOYSA-K
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    None
  • 重原子数:
    None
  • 可旋转键数:
    None
  • 环数:
    None
  • sp3杂化的碳原子比例:
    None
  • 拓扑面积:
    None
  • 氢给体数:
    None
  • 氢受体数:
    None

反应信息

  • 作为反应物:
    描述:
    3,5-二甲基吡唑mer-[RuCl3(tetramethylene sulfoxide-S)2(tetramethylene sulfoxide-O)]二氯甲烷 为溶剂, 反应 24.0h, 以83%的产率得到mer-[RuCl3(tetramethylene sulfoxide-S)(tetramethylene sulfoxide-O)(3,5-dimethylpyrazole)]
    参考文献:
    名称:
    含唑基配体的 Ru(iii)–TMSO复合物:合成和细胞毒性研究†
    摘要:
    的反应聚体将[RuCl - 3(S-TMSO)2(O-TMSO)](TMSO =四亚甲基砜)在二氯甲烷中与唑类(吡唑= PZH和3,5-二甲基吡= dmpzH)中产生的复合物聚体-将[RuCl 3(S-TMSO)(PZH)2 ] 1,聚体-将[RuCl 3(S-TMSO)(O-TMSO)(PZH)] 2,聚体-将[RuCl 3(S-TMSO)(dmpzH)2 ] 3和聚体-将[RuCl 3(S-TMSO)(O-TMSO)(dmpzH)] 4。使用分析,光谱和电化学技术以及单晶X射线衍射分析对这些配合物进行表征。对人成神经细胞瘤细胞系NB-Nu-39的细胞毒性分析显示,在吡唑环的3和5位带有甲基的化合物3和4对神经母细胞瘤细胞表现出显着的细胞毒性,IC 50值为50。 14.5μM和12.9μM。NAMI-A的IC 50值为12.4μM,非常接近4。相反,化合物1和2对神经母细胞瘤细胞没有明显的细胞毒活性(IC
    DOI:
    10.1039/c7nj03267f
  • 作为产物:
    描述:
    四甲基亚砜 、 hydrogen(tetramethylene sulfoxide) trans-bis(tetramethylene sulfoxide)tetrachlororuthenate(III) 在 AgBF4 作用下, 以 丙酮 为溶剂, 以80%的产率得到mer-[RuCl3(tetramethylene sulfoxide-S)2(tetramethylene sulfoxide-O)]
    参考文献:
    名称:
    新型卤素-四亚甲基亚砜-钌(II)和钌(III)配合物的合成与表征;顺-二氯四(四亚甲基亚砜)钌(II)和氢反式双(四亚甲基亚砜)四氯钌(III)的晶体结构
    摘要:
    在本文中,我们报告了以下钌(II)和钌(III)与四亚甲基亚砜(TMSO)的合成和表征:顺式RuCl2(TMSO)4(1),反式RuCl2(TMSO)4(2) ,相应的二溴衍生物顺式和反式RuBr2(TMSO)4(分别为3和4),(TMSO)H [反式-Ru(TMSO)2Cl4](5)和mer-RuCl3(TMSO)3(6) 。首次对大多数报道的配合物进行了描述,并为先前已知的配合物1和3提供了一种新的,简便的合成途径。描述了1和2在非质子传递性非配位溶剂溶液中的化学行为。在Ru(II)衍生物中,顺式异构体在热力学上更稳定,并且在四亚甲基亚砜溶液中观察到光化学驱动的顺式至反式异构化反应。我们还报告了通过三维X射线分析确定的顺式RuCl2(TMSO)4(1)和(TMSO)H [反式Ru(TMSO)2Cl4](5)的晶体结构。晶体数据:1,a = 9.104(2),b = 1.137(2),c
    DOI:
    10.1016/s0020-1693(00)85984-8
点击查看最新优质反应信息

文献信息

  • Synthesis and characterization of two new classes of ruthenium(III)-sulfoxide complexes with nitrogen donor ligands (L): Na[trans-RuCl4(R2SO)(L)] and mer, cis-RuCl3(R2SO)(R2SO)(L). The crystal structure of Na[trans-RuCl4(DMSO)(NH3)] · 2DMSO, Na[trans-RuCl4(DMSO)(Im)] · H2O, Me2CO (Im = imidazole) and mer, cis-RuCl3(DMSO)(DMSO)(NH3)
    作者:E. Alessio、G. Balducci、A. Lutman、G. Mestroni、M. Calligaris、W.M. Attia
    DOI:10.1016/s0020-1693(00)81659-x
    日期:1993.1
    respectively. In 5a and 5b, the DMSO ligand is S-bonded to Ru, with RuS bond distances (trans to N) of 2.2797(7) and 2.2956(6) A, respectively, while in 6a, one DMSO, trans to N, is S-bonded (RuS, 2.2714(6) A), and the other, trans to Cl, is O-bonded (RuO, 2.070(2) A). The RuCl bond distance, trans to O, is 2.3207(7) A. The RuCl bond distances, trans to Cl, are similar in all three compounds averaging 2
    摘要本文报道了两类新型的含氮配体(L)的化物-亚砜-Ru(III)衍生物的合成:Na [反式RuCl4(R2SO)(L)]和mer,cis- RuCl3(R2SO)(R2SO)(L)。还描述了它们在固态(IR)和溶液(NMR,UVVis)中的光谱表征。在溶液中进行的络合物的循环伏安法在每种情况下均显示出单电子且相当快速的Ru(III)/ Ru(II)电子转移。所观察到的形式势比其他Ru(III)络合物所报告的形式势要积极得多。净电荷以及DMSO的π酸性是导致此行为的因素。Na [反式RuCl4(DMSO)(NH3)]·2DMSO(5a),Na [反式RuCl4(DMSO)(Im)]·H2O,Me2CO 5b和mer的晶体结构,通过三维X射线分析确定了顺式RuCl3(DMSO)(DMSO)(NH3)(6a)。晶体数据为:a = 9.578(2),b = 12.480(2),c = 9.594(6)A,α=
  • Synthesis and crystal structures of carbonyl derivatives of chloride–tetramethylene sulfoxide–ruthenium(III) complexes: [RuCl3(TMSO)2(CO)] and [H(TMSO)2] [RuCl4(TMSO)(CO)]
    作者:Radhey S Srivastava、Frank R Fronczek
    DOI:10.1016/s0020-1693(01)00529-1
    日期:2001.10
    [H(TMSO)][RuCl4(TMSO)2] with carbon monoxide in the presence or absence of TMSO at ambient temperature and pressure. Complexes 1 and 2 represents the first examples of Ru(III) compounds bearing both tetramethylene sulfoxide and carbon monoxide ligands on the metal. Substitution of one of the two trans-S-bonded TMSO from the anion accompanied addition of one molecule of TMSO on the cation. Coordination of CO induces
    报道了[RuCl 3(TMSO)2(CO)](1)和[H(TMSO)2 ] [RuCl 4(TMSO)(CO)](2)的合成,光谱表征和晶体结构。这些配合物是通过在环境温度和压力下,在存在或不存在TMSO的情况下,将前体[ mer -RuCl 3(TMSO)3 ]和[H(TMSO)] [RuCl 4(TMSO)2 ]与一氧化碳反应制备的。 。配合物1和2代表在属上同时带有四亚甲基亚砜一氧化碳配体的Ru(III)化合物的第一个实例。阴离子上两个反式-S键合的TMSO之一被取代,同时在阳离子上添加了一个TMSO分子。CO的配位诱导TMSO配体的S-O键异构化。1的晶体是橘红色的针状单斜晶体,空间群C 2 / c,a = 26.446(2)Å,b = 8.8726(6)Å,c = 15.1093(8)Å,β = 107.427(4) °。的晶体2是橙色针,斜方晶系,空间群晶Pnma,一个= 11
  • Unexpected formation and structure elucidation of mer-[RuCl3(TMSO)(bpy)] derived from [H(TMSO)][trans-RuCl4(TMSO)2] under mild condition
    作者:Radhey S. Srivastava、Frank R. Fronczek
    DOI:10.1016/j.ica.2004.09.040
    日期:2005.2
    Treatment of [H(TMSO)][trans-RUCl4(TMSO)(2)] (1) with 2,2'-bipyridine (bpy) in ethanol at room temperature resulted an unknown mer-[RuCl3(TMSO)(bpy)] (3) and a known cis-[RuCl2(TMSO)(4)] (4) (TMSO = tetramethylene sulfoxide) complexes. The 3 was obtained by the substitution with bpy in mer-[RuCl3(TMSO)(3)] (2), whereas 4 was obtained by one-electron reduction of 2, suggesting that 2 is a precursor for both 3 and 4. The structure of 3 was determined by single crystal X-ray diffraction. The reaction is a new synthetic procedure for 3 and/or 3 and 4 in mild reaction conditions from the anionic complex 1. It involves simultaneous substitution and redox reaction. This is the first known example of precisely characterized Ru(III)-chloride-TMSO-bpy-complex derived from anionic [H(TMSO)][trans-RuCl4(TMSO)(2)] at room temperature. (C) 2004 Elsevier B.V. All rights reserved.
  • Formation and molecular structure of novel Ru(III) dimers of a symmetric antitumor drug analogue
    作者:Radhey S. Srivastava、Frank R. Fronczek、Liz M. Romero
    DOI:10.1016/j.ica.2004.01.026
    日期:2004.6
    The symmetrical anionic and neutral dimers [H(TMSO)(2)](2) trans-[RuCl4(TMSO)}(2)](mu-pyz) (1), and mer-[RuCl3(TMSO)(2)}(2)](mu-pyz) (2) were isolated by the reaction of [H(TMSO)] trans-[RuCl4(TMSO)(2)] and mer-[RuCl3(TMSO)(3)] with heterocyclic nitrogen donor ligand pyrazine (pyz) at room temperature. These complexes can be regarded as unprecedented examples in the general Creutz-Taube family of ruthenium dimers. Each ruthenium center in I and 2 has a coordination environment akin to that of known anionic and neutral monomeric Ru(III) complexes. Crystals of 1 acetone are orange, needle like, space group P1, a = 10.419(3) Angstrom, b = 10.539(3) Angstrom, c = 12.595(5) Angstrom, alpha = 69.837(16)degrees, beta = 69.968(15)degrees, gamma = 74.330(15)degrees and crystals of 2.4TMSO are orange prisms, trigonal, space group R3, a = 33.971(5) Angstrom, b = 33.971(5) Angstrom, c = 12.210(2) Angstrom, alpha = 90degrees, beta = 90degrees and gamma = 120degrees. (C) 2004 Elsevier B.V. All rights reserved.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)